Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin

NCT00998686 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 650

Last updated 2010-08-11

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the safety and tolerability of dutogliptin over 52 weeks.

Conditions

Interventions

DRUG

dutogliptin

400 mg

DRUG

sitagliptin

100 mg

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY
  • Phenomix

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2011-10-31
Completion
2011-11-30

Countries

  • United States
  • Argentina
  • Czechia
  • India
  • Peru
  • Poland

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00998686 on ClinicalTrials.gov